Following the report of two cases, an uncontrolled, open label phase I/IIa clinical trial of low dose IL-2 is ongoing (NCT01988506): preliminary results in two AIH patients showed short-term Treg expansion without safety issues [220]. Here, IL2 is linked to autoimmune hepatitis.